‘Be intentional, often aggressive’ in managing ocular complications of cancer drugs

PHOENIX — Mirvetuximab, an antibody drug conjugate for the treatment of certain types of cancer, can lead to adverse ocular events in the early weeks of treatment, according to a poster here. Across four cases of folate receptor-alpha positive, platinum-resistant epithelial ovarian and fallopian tube cancer, three patients developed corneal subepithelial microcysts in the early weeks of treatment